Seizures in AD are associated with accelerated cognitive decline [57], more pronounced differences in CSF AD biomarkers [3], and greater AD neuropathology (e.g., decreased brain weight, increased phosphorylated tau [pTau], increased white matter beta amyloid [Aβ] plaque pathology) [13]. This evidence concerns the gene MAPT and Alzheimer disease.